An ecological measure of immune-cancer colocalization as a prognostic factor for breast cancer

Maley, Carlo C.; Koelble, Konrad; Natrajan, Rachael; Aktipis, Athena; Yuan, Yinyin

doi:10.1186/s13058-015-0638-4

Breast Cancer Research

Table 2 Prognostic value of immune-cancer cell colocalization measures using univariate (white background) and multivariate (gray background) Cox regression in the discovery and validation cohorts for all breast cancers and Her2+ cancer defined by PAM50 and by SNP6

From: An ecological measure of immune-cancer colocalization as a prognostic factor for breast cancer

		Hazard ratio (95 % CI)	P value	Conc	Hazard ratio (95 % CI)	P value	Conc
All breast cancers		Discovery cohort (475 samples)			Validation cohort (514 samples)
	Morisita	0.6 (0.42–0.86)	0.0052	0.56	0.41 (0.25–0.7)	0.00067	0.75
	Lymphnode	2.36 (1.62–3.46)	9.4×10⁻⁶	0.607	3.55 (1.92–6.56)	5.4×10⁻⁵	0.73
	Size	2.26 (1.63–3.13)	8.9×10⁻⁷	0.612	2.42 (1.57–3.73)	6.5×10⁻⁵	0.74
	Grade	2.18 (1.59–3.01)	1.8×10⁻⁶	0.627	2.76 (1.66–4.59)	9.6×10⁻⁵	0.619
	Morisita	0.59 (0.41–0.85)	0.005	0.699	0.4 (0.24–0.69)	0.00085	0.9
	Lymphnode	1.78 (1.19–2.65)	0.0046		2.2 (1.16–4.17)	0.015
	Size	1.89 (1.34–2.68)	0.00033		1.88 (1.17–3.03)	0.0096
	Grade	1.82 (1.31–2.53)	0.00035		2.58 (1.53–4.34)	0.00038
Luminal A		Discovery cohort (150 samples)			Validation cohort (178 samples)
	Morisita	0.13 (0.04–0.45)	0.00014	0.715	0.29 (0.07–1.14)	0.059	0.618
	Lymphnode	1.43 (0.46–4.42)	0.54	0.552	1.93 (0.5–7.47)	0.33	0.576
	Size	4.38 (1.46–13.14)	0.0067	0.692	2.13 (0.69–6.62)	0.19	0.58
	Grade	1.84 (0.83–4.1)	0.13	0.619	2.47 (0.9–6.79)	0.071	0.62
	Morisita	0.15 (0.04–0.53)	0.003	0.839	0.33 (0.08–1.31)	0.11	0.733
	Lymphnode	1.01 (0.3–3.41)	0.98		1.18 (0.29–4.8)	0.81
	Size	4.17 (0.99–17.56)	0.052		2.09 (0.54–8.14)	0.29
	Grade	1.44 (0.61–3.42)	0.41		2.47 (0.86–7.13)	0.095
Her2 by PAM50		Discovery cohort (65 samples)			Validation cohort (42 samples)
	Morisita	0.29 (0.15–0.57)	0.00017	0.65	0.12 (0.02–0.61)	0.0022	0.808
	Lymphnode	3.59 (1.55–8.3)	0.0015	0.64	NA	0.0098	0.666
	Size	1.74 (0.97–3.12)	0.064	0.577	4.83 (1.48–15.78)	0.0051	0.689
	Grade	1.68 (0.78–3.62)	0.18	0.574	0.29 (0.07–1.23)	0.075	0.529
	Morisita	0.38 (0.17–0.84)	0.016	0.734	0.1 (0.01–0.66)	0.017	0.896
	Lymphnode	2.2 (0.87–5.57)	0.095		NA	1
	Size	1.47 (0.83–2.61)	0.18		0.78 (0.16–3.83)	0.76
	Grade	1.8 (0.81–4.02)	0.15		0.37 (0.08–1.74)	0.21
Her2+ by SNP6		Discovery cohort (72 samples)			Validation cohort (56 samples)
	Morisita	0.49 (0.25–0.98)	0.039	0.597	0.05 (0.01–0.4)	9.3×10 ⁻⁵	0.808
	Lymphnode	3.31 (1.5–7.31)	0.0017	0.637	7.31 (0.89–59.98)	0.031	0.666
	Size	1.49 (0.82–2.73)	0.19	0.557	3.52 (1–12.36)	0.05	0.689
	Grade	1.56 (0.68–3.59)	0.29	0.551	1.41 (0.36–5.58)	0.62	0.529
	Morisita	0.44 (0.21–0.91)	0.027	0.722	0.03 (0–0.3)	0.0031	0.896
	Lymphnode	3.68 (1.49–9.09)	0.0048		2.65 (0.28–24.99)	0.39
	Size	2.01 (1–4.04)	0.049		3.42 (1.1–10.64)	0.034
	Grade	1.46 (0.57–3.75)	0.43		1.86 (0.33–10.42)	0.48

Multivariate Cox regression includes lymph node status, tumor size, tumor grade, and the colocalization measure; age as a continuous or dichotomized variable using the optimal cutoff search was not associated with survival in all cancers or any subtype and hence was not considered. Bold text indicates significant p values for the newly proposed measures. Conc concordance, Her2+ human epidermal growth factor receptor 2-positive

Back to article page

ISSN: 1465-542X

Contact us

Submission enquiries: journalsubmissions@springernature.com